Table 4.
Number of severe exacerbations and treatments in the 12 months before the study visit.
| All (N = 3066) | SABA mono (n = 89) | SABA as an add-on (n = 1594) | ICS mono (n = 429) | ICS/LABA (fixed dose) (n = 2581) |
OCS short course (n = 910) | |
|---|---|---|---|---|---|---|
| Number of severe exacerbations 12 months before the study visit, n (%) | ||||||
| 0 | 1917 (62.5) | 66 (74.2) | 869 (54.5) | 245 (57.1) | 1584 (61.4) | 189 (20.8) |
| 1 | 585 (19.1) | 14 (15.7) | 364 (22.8) | 81 (18.9) | 514 (19.9) | 333 (36.6) |
| 2 | 241 (7.9) | 2 (2.2) | 162 (10.2) | 48 (11.2) | 209 (8.1) | 145 (15.9) |
| 3 | 151 (4.9) | 5 (5.6) | 81 (5.1) | 32 (7.5) | 120 (4.6) | 110 (12.1) |
| 4 | 66 (2.2) | 1 (1.1) | 38 (2.4) | 8 (1.9) | 60 (2.3) | 50 (5.5) |
| 5 | 40 (1.3) | 1 (1.1) | 26 (1.6) | 3 (0.7) | 36 (1.4) | 28 (3.1) |
| >5 | 66 (2.2) | 0 (0.0) | 54 (3.4) | 12 (2.8) | 58 (2.2) | 55 (6.0) |
| Total (n) | 3066 | 89 | 1594 | 429 | 2581 | 910 |
ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; mono, monotherapy; OCS, oral corticosteroids; SABA, short-acting β2-agonist